Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Baseline participants’ demographics by disease activity stratification, as measured by RAPID3 (N = 249)

From: Barriers to treatment optimization and achievement of patients’ goals: perspectives from people living with rheumatoid arthritis enrolled in the ArthritisPower registry

Mean (SD) unless otherwise specifiedAll survey participants (N = 249)High disease activity (n = 175)Moderate/low disease activity or near REM (n = 74)p valuea
Age, years51.7 (11.0)50.9 (10.6)53.7 (11.5)0.06
Females, n (%)229 (92.0)163 (93.1)66 (89.2)0.29
Ethnicity, white, n (%)225 (90.4)154 (88.0)71 (96.0)0.05
Time since diagnosis, years (SD)11.0 (9.5)10.8 (9.3)11.5 (10.1)0.62
Some college education or above, n (%)215 (86.4)150 (85.7)65 (87.8)0.66
Full-time employment, n (%)83 (33.3)58 (33.1)25 (33.8)0.92
Private insurance, n (%)154 (61.9)112 (64.0)42 (56.8)0.28
Current RA therapy, n (%)
 Non-biologic DMARDs only72 (28.9)54 (30.9)18 (24.3)0.30
 Biologic DMARDs150 (60.2)106 (60.6)44 (59.5)0.87
 Steroid/NSAID/other/no treatmentb27 (10.8)15 (8.6)12 (16.2)0.08
Patient-reported outcomes, median (IQR)
 RAPID3 (0–30 scale)15.0 (12.0–19.0)18.0 (15.0–20.0)8.0 (6.0–11.0)< 0.0001
 PROMIS-CAT measures (0–100 scale)
  Pain interference63.3 (60.3–66.9)65.5 (62.7–67.8)58.0 (55.8–61.5)< 0.0001
  Fatigue63.0 (58.7–67.9)65.7 (62.3–69.4)56.7 (50.8–62.3)< 0.0001
  Physical function37.8 (34.0–40.8)35.5 (32.5–38.6)43.2 (39.5–45.8)< 0.0001
  Sleep disturbance59.2 (54.3–63.0)60.8 (55.8–64.9)55.6 (50.4–61.8)< 0.0001
  1. Participants with near REM: RAPID3 scores 1–3; low disease activity: RAPID3 scores 4–6; moderate disease activity: RAPID3 scores 7–12; high disease activity: RAPID3 scores 13–30. DMARD disease-modifying antirheumatic drug, IQR interquartile range, NSAID non-steroidal anti-inflammatory drug, PROMIS-CAT Patient-Reported Outcomes Measurement Information System – Computerized Adaptive Test, RA rheumatoid arthritis, RAPID3 Routine Assessment of Patient Index Data 3, REM remission, SD standard deviation
  2. aStatistical significance between moderate/low and high disease activity patient groups, p < 0.05; t tests were performed for continuous variables and chi square tests for categorical variables; p values are nominal in nature and should be interpreted in an exploratory manner
  3. bParticipants received prior DMARD treatment before baseline. PROMIS-CAT cut-offs for normal (score ≤ 55), low (score > 55–60), and medium (score > 60–70), and high pain interference, fatigue, and sleep disturbance (score > 70); PROMIS-CAT cut-offs for normal (score ≥ 45), low (score 40 < 45), medium (30 < 40), and high physical function (score < 30). Possible PROMIS-CAT scores ranged from 0 to 100